Premium
COVID‐19 infection in patients with intestinal failure: UK experience
Author(s) -
Allan P. J.,
Ambrose T.,
Mountford C.,
Bond A.,
Donnellan C.,
Boyle R.,
Calvert C.,
Cernat E.,
Clarke E.,
Cooper S. C.,
Donnelly S.,
Evans B.,
Glynn M.,
Hewett R.,
Holohan A. S.,
Leitch E. F.,
LouisAuguste J.,
Mehta S.,
Naik S.,
Nightingale J.,
Rafferty G.,
Rodrigues A.,
Sharkey L.,
Small M.,
Teubner A.,
Urs A.,
Wyer N.,
Lal S.
Publication year - 2021
Publication title -
journal of parenteral and enteral nutrition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.935
H-Index - 98
eISSN - 1941-2444
pISSN - 0148-6071
DOI - 10.1002/jpen.2087
Subject(s) - medicine , intestinal failure , cohort , parenteral nutrition , covid-19 , pandemic , cohort study , retrospective cohort study , pediatrics , disease , intensive care medicine , infectious disease (medical specialty)
Background The direct effect of the coronavirus disease 2019 (COVID‐19) pandemic on patients with intestinal failure (IF) has not been described. Methods We conducted a nationwide study of UK IF centers to evaluate the infection rates, presentations, and outcomes in patients with types 2 and 3 IF. Results A total of 45 patients with IF contracted COVID‐19 between March and August 2020; this included 26 of 2191 (1.2%) home parenteral nutrition (HPN)–dependent adults and 19 of 298 (6.4%) adults hospitalized with type 2 IF. The proportion of patients receiving nursing care for HPN administration was higher in those with community‐acquired COVID‐19 (66.7%) than the proportion in the entire HPN cohort (26.1%; P < .01). Two HPN‐dependent and 1 hospitalized patient with type 2 IF died as a direct consequence of the virus (6.7% of 45 patients with types 2 or 3 infected). Conclusion This is the first study to describe the outcomes of COVID‐19 in a large cohort of patients requiring long‐term PN. Methods to reduce hospital and community nosocomial spread would likely be beneficial.